Summit Therapeutics (SMMT) to Release Quarterly Earnings on Tuesday

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) will likely be releasing its earnings data before the market opens on Tuesday, February 18th. Analysts expect Summit Therapeutics to post earnings of ($0.08) per share for the quarter.

Summit Therapeutics Stock Up 2.1 %

NASDAQ:SMMT traded up $0.45 during trading hours on Wednesday, reaching $21.53. 945,045 shares of the company's stock were exchanged, compared to its average volume of 2,249,086. Summit Therapeutics has a 1-year low of $2.10 and a 1-year high of $33.89. The firm has a market capitalization of $15.87 billion, a price-to-earnings ratio of -76.87 and a beta of -0.88. The company has a 50-day moving average of $19.66 and a 200 day moving average of $18.82.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SMMT. JMP Securities assumed coverage on Summit Therapeutics in a report on Monday, November 4th. They set a "market outperform" rating and a $32.00 price target on the stock. Wells Fargo & Company initiated coverage on Summit Therapeutics in a research note on Wednesday, December 11th. They issued an "overweight" rating and a $30.00 target price on the stock. Jefferies Financial Group started coverage on Summit Therapeutics in a report on Friday, December 6th. They issued a "buy" rating and a $31.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $44.00 price target on shares of Summit Therapeutics in a report on Tuesday, January 21st. Finally, Truist Financial initiated coverage on shares of Summit Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $35.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Summit Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $33.57.

Summit Therapeutics Company Profile

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.